![]() |
||||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Fusion gene ID: 37773 |
FusionGeneSummary for TET2_OSTC |
![]() |
Fusion gene information | Fusion gene name: TET2_OSTC | Fusion gene ID: 37773 | Hgene | Tgene | Gene symbol | TET2 | OSTC | Gene ID | 54790 | 58505 |
Gene name | tet methylcytosine dioxygenase 2 | oligosaccharyltransferase complex non-catalytic subunit | |
Synonyms | KIAA1546|MDS | DC2 | |
Cytomap | 4q24 | 4q25 | |
Type of gene | protein-coding | protein-coding | |
Description | methylcytosine dioxygenase TET2probable methylcytosine dioxygenase TET2tet oncogene family member 2 | oligosaccharyltransferase complex subunit OSTChydrophobic protein HSF-28oligosaccharyltransferase complex subunit (non-catalytic) | |
Modification date | 20180523 | 20180523 | |
UniProtAcc | Q6N021 | Q9NRP0 | |
Ensembl transtripts involved in fusion gene | ENST00000545826, ENST00000513237, ENST00000540549, ENST00000380013, ENST00000305737, ENST00000394764, ENST00000504042, ENST00000413648, | ENST00000361564, ENST00000512478, ENST00000505745, | |
Fusion gene scores | * DoF score | 6 X 4 X 6=144 | 1 X 1 X 1=1 |
# samples | 7 | 1 | |
** MAII score | log2(7/144*10)=-1.04064198449735 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(1/1*10)=3.32192809488736 | |
Context | PubMed: TET2 [Title/Abstract] AND OSTC [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | TET2 | GO:0006211 | 5-methylcytosine catabolic process | 24315485 |
Hgene | TET2 | GO:0006493 | protein O-linked glycosylation | 23222540 |
Hgene | TET2 | GO:0080111 | DNA demethylation | 24315485 |
![]() (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
TCGA | LD | KIRC | TCGA-BP-4770-01A | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
![]() * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
intron-3CDS | ENST00000545826 | ENST00000361564 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
intron-3CDS | ENST00000545826 | ENST00000512478 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
intron-intron | ENST00000545826 | ENST00000505745 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
intron-3CDS | ENST00000513237 | ENST00000361564 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
intron-3CDS | ENST00000513237 | ENST00000512478 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
intron-intron | ENST00000513237 | ENST00000505745 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
intron-3CDS | ENST00000540549 | ENST00000361564 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
intron-3CDS | ENST00000540549 | ENST00000512478 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
intron-intron | ENST00000540549 | ENST00000505745 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
5UTR-3CDS | ENST00000380013 | ENST00000361564 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
5UTR-3CDS | ENST00000380013 | ENST00000512478 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
5UTR-intron | ENST00000380013 | ENST00000505745 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
5UTR-3CDS | ENST00000305737 | ENST00000361564 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
5UTR-3CDS | ENST00000305737 | ENST00000512478 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
5UTR-intron | ENST00000305737 | ENST00000505745 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
5UTR-3CDS | ENST00000394764 | ENST00000361564 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
5UTR-3CDS | ENST00000394764 | ENST00000512478 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
5UTR-intron | ENST00000394764 | ENST00000505745 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
3UTR-3CDS | ENST00000504042 | ENST00000361564 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
3UTR-3CDS | ENST00000504042 | ENST00000512478 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
3UTR-intron | ENST00000504042 | ENST00000505745 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
intron-3CDS | ENST00000413648 | ENST00000361564 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
intron-3CDS | ENST00000413648 | ENST00000512478 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
intron-intron | ENST00000413648 | ENST00000505745 | TET2 | chr4 | 106111662 | + | OSTC | chr4 | 109588403 | + |
Top |
FusionProtFeatures for TET2_OSTC |
![]() |
Hgene | Tgene |
TET2 | OSTC |
Dioxygenase that catalyzes the conversion of themodified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in active DNAdemethylation. Has a preference for 5-hydroxymethylcytosine in CpGmotifs. Also mediates subsequent conversion of 5hmC into 5-formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine(5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probablyconstitutes the first step in cytosine demethylation. Methylationat the C5 position of cytosine bases is an epigenetic modificationof the mammalian genome which plays an important role intranscriptional regulation. In addition to its role in DNAdemethylation, also involved in the recruitment of the O-GlcNActransferase OGT to CpG-rich transcription start sites of activegenes, thereby promoting histone H2B GlcNAcylation by OGT.{ECO:0000269|PubMed:19483684, ECO:0000269|PubMed:21057493,ECO:0000269|PubMed:21817016, ECO:0000269|PubMed:23222540,ECO:0000269|PubMed:23353889, ECO:0000269|PubMed:24315485}. | May act as substrate-specific component of the N-oligosaccharyl transferase (OST) complex which catalyzes thetransfer of a high mannose oligosaccharide from a lipid-linkedoligosaccharide donor to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains. May beinvolved in N-glycosylation of APP (amyloid-beta precursorprotein). Can modulate gamma-secretase cleavage of APP byenhancing endoprotelysis of PSEN1. {ECO:0000269|PubMed:21768116,ECO:0000305}. |
![]() * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for TET2_OSTC |
![]() (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
* Fusion transcript sequences (only coding sequence (CDS) region). |
* Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for TET2_OSTC |
![]() |
![]() |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
TET2 | TBC1D4, TCF3, PAN2, OGT, VPRBP, DDB1, EBF1, NONO, SEMG1 | OSTC | ATP13A2, EDA, EED, DLK1, ATP2B2, SLC39A9, SCN3B, DPEP1, GYG2 |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for TET2_OSTC |
![]() (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for TET2_OSTC |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | TET2 | C0079774 | Peripheral T-Cell Lymphoma | 2 | CTD_human |
Hgene | TET2 | C0007134 | Renal Cell Carcinoma | 1 | CTD_human |
Hgene | TET2 | C0020981 | Angioimmunoblastic Lymphadenopathy | 1 | CTD_human |
Hgene | TET2 | C0023487 | Acute Promyelocytic Leukemia | 1 | CTD_human |
Hgene | TET2 | C0027643 | Neoplasm Recurrence, Local | 1 | CTD_human |
Hgene | TET2 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
Hgene | TET2 | C0036920 | Sezary Syndrome | 1 | CTD_human |
Hgene | TET2 | C3463824 | MYELODYSPLASTIC SYNDROME | 1 | CTD_human;HPO |